MBRX
Price:
$2.77
Market Cap:
$8.32M
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma mul...[Read more]
Industry
Biotechnology
IPO Date
2016-06-02
Stock Exchange
NASDAQ
Ticker
MBRX
According to Moleculin Biotech, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -583737.00. This represents a change of -456.15% compared to the average of 163.90K of the last 4 quarters.
The mean historical Enterprise Value of Moleculin Biotech, Inc. over the last ten years is 15.39M. The current -583737.00 Enterprise Value has changed -479.18% with respect to the historical average. Over the past ten years (40 quarters), MBRX's Enterprise Value was at its highest in in the September 2016 quarter at 60.23M. The Enterprise Value was at its lowest in in the September 2022 quarter at -19569738.70.
Average
15.39M
Median
19.81M
Minimum
-20754788.80
Maximum
45.78M
Discovering the peaks and valleys of Moleculin Biotech, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 51.59%
Maximum Annual Enterprise Value = 45.78M
Minimum Annual Increase = -164.47%
Minimum Annual Enterprise Value = -20754788.80
Year | Enterprise Value | Change |
---|---|---|
2023 | 2.47M | -119.96% |
2022 | -12373351.90 | -40.38% |
2021 | -20754788.80 | -164.47% |
2020 | 32.19M | 19.64% |
2019 | 26.91M | 35.86% |
2018 | 19.81M | -26.16% |
2017 | 26.82M | 51.59% |
2016 | 17.70M | -61.35% |
The current Enterprise Value of Moleculin Biotech, Inc. (MBRX) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-10219432.26
5-year avg
5.69M
10-year avg
15.39M
Moleculin Biotech, Inc.’s Enterprise Value is less than Catalyst Biosciences, Inc. (19.42M), less than Pulmatrix, Inc. (13.47M), less than Cyclacel Pharmaceuticals, Inc. (-435680.00), less than Akari Therapeutics, Plc (28.71M), less than Onconova Therapeutics, Inc. (4.51M), less than Bio-Path Holdings, Inc. (2.78M), less than AN2 Therapeutics, Inc. (16.39M), less than Miromatrix Medical Inc. (90.06M), less than Inhibikase Therapeutics, Inc. (195.43M), less than PMV Pharmaceuticals, Inc. (48.29M), less than Anebulo Pharmaceuticals, Inc. (35.94M), greater than Diffusion Pharmaceuticals Inc. (-1447403.00), less than Capricor Therapeutics, Inc. (797.65M), less than NextCure, Inc. (10.45M), less than Panbela Therapeutics, Inc. (7.82M), less than Virax Biolabs Group Limited (5.19M), greater than Allarity Therapeutics, Inc. (-12249054.00), greater than ContraFect Corporation (-2860000.00), less than Avenue Therapeutics, Inc. (1.50M),
Company | Enterprise Value | Market cap |
---|---|---|
19.42M | $19.42M | |
13.47M | $24.25M | |
-435680.00 | $2.55M | |
28.71M | $29.96M | |
4.51M | $20.90M | |
2.78M | $3.32M | |
16.39M | $49.90M | |
90.06M | $92.95M | |
195.43M | $196.20M | |
48.29M | $83.83M | |
35.94M | $37.34M | |
-1447403.00 | $8.98M | |
797.65M | $864.38M | |
10.45M | $32.77M | |
7.82M | $1.57M | |
5.19M | $8.55M | |
-12249054.00 | $4.88M | |
-2860000.00 | $0 | |
1.50M | $4.10M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Moleculin Biotech, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Moleculin Biotech, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Moleculin Biotech, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Moleculin Biotech, Inc. (MBRX)?
What is the 3-year average Enterprise Value for Moleculin Biotech, Inc. (MBRX)?
What is the 5-year average Enterprise Value for Moleculin Biotech, Inc. (MBRX)?
How does the current Enterprise Value for Moleculin Biotech, Inc. (MBRX) compare to its historical average?